Sana Biotechnology
The profile is currenly unclaimed by the seller. All information is provided by CB Insights.
Founded Year
2018Stage
IPO | IPOTotal Raised
$700MDate of IPO
2/4/2021Market Cap
1.60BStock Price
8.41Research containing Sana Biotechnology
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Sana Biotechnology in 3 CB Insights research briefs, most recently on Aug 4, 2020.
Aug 4, 2020
Here Are Q2’s Most Active Healthcare InvestorsJul 30, 2020
Q2’20 Was A Record-Breaking Quarter For HealthcareExpert Collections containing Sana Biotechnology
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Sana Biotechnology is included in 2 Expert Collections, including Biopharma Tech.
Biopharma Tech
5,241 items
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Regenerative Medicine
1,818 items
Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).
Sana Biotechnology Patents
Sana Biotechnology has filed 4 patents.
The 3 most popular patent topics include:
- Biotechnology
- Clusters of differentiation
- Immune system
Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
3/30/2021 | Transcription factors, Membrane biology, Protein domains, Clusters of differentiation, Molecular biology | Application |
Application Date | 3/30/2021 |
---|---|
Grant Date | |
Title | |
Related Topics | Transcription factors, Membrane biology, Protein domains, Clusters of differentiation, Molecular biology |
Status | Application |
Latest Sana Biotechnology News
Aug 12, 2022
Complexity is the attraction: Steve Harr on the pull of cell and gene therapy Sana CEO tells The BioCentury Show his approach to making a step difference in the field By C. Simone Fishburn, Editor in Chief August 11, 2022 11:57 AM UTC Cell therapy and gene therapy aren’t distinct opportunities in Steve Harr’s eyes. Rather, the platform he is building as president and CEO of Sana is one that combines the two, and capitalizes on the collective knowledge and experience of the Juno graduates who found themselves wanting to do more, after the company’s acquisition by Celgene. On The BioCentury Show, Harr discussed his view of how the cell and gene therapy field is evolving, and both the technical and talent challenges that will be required to drive success at scale. Harr launched Sana Biotechnology Inc. (NASDAQ:SANA) together with Chairman Hans Bishop in January 2019, with ambitious goals to fix any cell in the body that’s been damaged, replace any cell that’s too far damaged, and have “access never determined by where a patient is born,” he said. The company has made a splash, announcing $700 million in venture financing in 2020, and going public a year later with one of the biggest IPOs in biotech history, raising $675.6 million. Bishop had been president and CEO of Juno Therapeutics Inc. and Harr CFO and head of corporate development, leading the deal with Celgene Corp. that closed in March 2018. Celgene was acquired by Bristol Myers Squibb Co. (NYSE:BMY) in November 2019. Harr said that after the acquisition, many of the Juno team felt there was unfinished business, not having gotten drugs across the finish line, and there was momentum to work together again. He said the complexity of the goal was the attraction, but it was not simple to work out the best operating model. “If there’s ever a book written on Sana, Chapter One will be about the decision we made out of the gate, which was to start the company to build our capabilities more or less at equal size and scale across three different cities: Seattle, San Francisco, and Cambridge.” That allowed them to tap into different talent pools, but also added further challenges in what is already a complex area. “History will be the judge,” as to whether it was a good decision or not, said Harr. Purchase Reprint/Distribution Rights
Sana Biotechnology Web Traffic
Sana Biotechnology Rank
When was Sana Biotechnology founded?
Sana Biotechnology was founded in 2018.
Where is Sana Biotechnology's headquarters?
Sana Biotechnology's headquarters is located at 188 East Blaine Street, Seattle.
What is Sana Biotechnology's latest funding round?
Sana Biotechnology's latest funding round is IPO.
How much did Sana Biotechnology raise?
Sana Biotechnology raised a total of $700M.
Who are the investors of Sana Biotechnology?
Investors of Sana Biotechnology include F-Prime Capital, Flagship Pioneering, ARCH Venture Partners, WRF Capital, Amity Ventures and 14 more.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.